Steven D. Shnyder

Sort by:

Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor

Tracey J. Harvey, Drew Burdon, +7 authors John D. Chester
Gene Therapy
2010

We have assessed the ability of bispecific fusion proteins to improve adenovirus-mediated transfer of therapeutic and marker transgenes. We constructed an expression vector that can be easily… (More)

Abstract A16: Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model

Andrew Keith Powell, Steven D. Shnyder, +4 authors Gregg K Smith
2009

CYT997 is an orally bioavailable small molecule vascular‐disrupting agent (VDA) that is currently being investigated in Phase II clinical studies. In vitro efficacy studies have demonstrated that… (More)

Non-invasive molecular imaging for preclinical cancer therapeutic development.

Alice C O'Farrell, Steven D. Shnyder, Gemma Marston, Patricia Louise Coletta, Jason H Gill
British journal of pharmacology
2013

Molecular and non-invasive imaging are rapidly emerging fields in preclinical cancer drug discovery. This is driven by the need to develop more efficacious and safer treatments, the advent of… (More)

Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo

Tracey J. Harvey, Ivo M. Hennig, +5 authors John D. Chester
Cancer Gene Therapy
2011

Hypoxia is an important factor in tumor growth. It is associated with resistance to conventional anticancer treatments. Gene therapy targeting hypoxic tumor cells therefore has the potential to… (More)

In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine.

Karleen M Nicholson, Roger M. Phillips, Steven D. Shnyder, Michael Charles Bibby
European journal of cancer
2002

LS 4477 and LS 4559, two of a series of N-acyl-aminoalkyl phenyl ethers, are rationally designed compounds based on the tubulin binder estramustine. This study investigated their mechanism of action… (More)

The Evaluation of Selected Ghanaian Medicinal Plants for Cytotoxic Activities

Cancer is still responsible for many deaths worldwide. Therefore, the need for an effective management, treatment and cure of cancer is undoubtedly crucial. In Ghana, several plants or herbal… (More)

A Cytotoxic Diterpenoid from Croton Membranaceus, the Major Constituent of Anticancer Herbal Formulations Used in Ghana

Marcel Tunkumgnen Bayor, John Sefah K. Ayim, +4 authors Colin W. Wright
2008

Abstract #LB-211: CYT997: Preclinical studies on the antivascular effects and mode of action of a phase II vascular disrupting agent.

David J Segal, Pradnya Gangatirkar, +7 authors Emmanuelle Fantino
2009

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO CYT997 is an orally available synthetic small molecule that is currently in phase II clinical studies within different oncology settings. CYT997 has… (More)

Abstract 4541: Tumor-selective bioactivation of duocarmycin bioprecursors by cytochrome P450 enzymes provides an opportunity to treat drug-resistant breast cancer cells

Steven D. Shnyder, Paul M Loadman, +4 authors Klaus Pors
2015

Abstract 3105: Probing cytochrome P450 activity with benzofuran-based duocarmycins in a panel of head and neck cancer cell lines and CYP1A1, 1B1 and CYP2W1 transfected cell lines

Daniela Figueiredo Simões Presa, Paul M Loadman, +8 authors Klaus Pors
2016

Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Background: The cytochrome P450 (CYP) isoforms CYP1A1, 1B1 and 2W1 are highly expressed in tumour tissue and… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences